146 related articles for article (PubMed ID: 15288618)
1. A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil.
Bozdayi AM; Eyigun CP; Turkyilmaz AR; Avci IY; Pahsa A; Yurdaydin C
J Clin Virol; 2004 Sep; 31(1):76-7. PubMed ID: 15288618
[No Abstract] [Full Text] [Related]
2. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
4. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
5. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
Jacob JR; Korba BE; Cote PJ; Toshkov I; Delaney WE; Gerin JL; Tennant BC
Antiviral Res; 2004 Aug; 63(2):115-21. PubMed ID: 15302140
[TBL] [Abstract][Full Text] [Related]
6. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
8. Adefovir for lamivudine resistant HBV: more than meets the eye.
Di Marco V; Craxì A
J Hepatol; 2007 Oct; 47(4):618-9; author reply 619-20. PubMed ID: 17697727
[No Abstract] [Full Text] [Related]
9. [Lamivudine and adefovir dipivoxil combination treatment for liver cirrhosis patients with CHB].
Yang DH; Xie SF; Wang YM; Zhao NF; Li MW
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):473-4. PubMed ID: 18579006
[No Abstract] [Full Text] [Related]
10. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
Aloman C; Wands JR
Hepatology; 2003 Dec; 38(6):1584-7. PubMed ID: 14655682
[No Abstract] [Full Text] [Related]
11. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
13. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
15. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
16. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
Mutimer D
J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
[No Abstract] [Full Text] [Related]
17. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
Herreros de Tejada Echanojáuregui A; Moreno Planas JM; Rubio González E; Portero Azorin F; López Monclús J; Revilla Negro J; Lucena de la Poza JL; Sánchez Turrión V; Barrios Peinado C; Cuervas-Mons Martínez V
Transplant Proc; 2005 Apr; 37(3):1507-8. PubMed ID: 15866657
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Zhang WX; Lai V; Mutimer D; Mirza D
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):154-6. PubMed ID: 16481305
[TBL] [Abstract][Full Text] [Related]
19. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
